Editorial
doi: 10.2147/vhrm.2006.2.2.95.
Risk of cardiovascular events and cyclooxygenase-2 inhibitors
- PMID: 17319452
- PMCID: PMC1993996
- DOI: 10.2147/vhrm.2006.2.2.95
Item in Clipboard
Editorial
Risk of cardiovascular events and cyclooxygenase-2 inhibitors
Vasc Health Risk Manag.
2006.
No abstract available
Similar articles
-
[Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib].Med Klin (Munich). 2006 Aug 15;101(8):673-5; author reply 678-9. Med Klin (Munich). 2006. PMID: 17051669 German. No abstract available.
-
Cardiovascular risk of selective cyclooxygenase-2 inhibitors.J Cardiovasc Pharmacol Ther. 2005 Jun;10(2):95-101. doi: 10.1177/107424840501000203. J Cardiovasc Pharmacol Ther. 2005. PMID: 15965560 Review.
-
[Overestimated].Med Klin (Munich). 2006 Aug 15;101(8):676-7; author reply 678-9. Med Klin (Munich). 2006. PMID: 17051671 German. No abstract available.
-
Risks and benefits of celecoxib to prevent colorectal adenomas.N Engl J Med. 2006 Nov 30;355(22):2371; author reply 2371-3. doi: 10.1056/NEJMc062700. N Engl J Med. 2006. PMID: 17135594 No abstract available.
-
COX-2 inhibitors and the risk for cardiovascular events: a re-evaluation of the data and proposed mechanisms.S D J Med. 2005 Jul;58(7):269-72. S D J Med. 2005. PMID: 16425936 Review. No abstract available.
Cited by
-
Evaluation of the Antinociceptive, Antiallodynic, Antihyperalgesic and Anti-Inflammatory Effect of Polyalthic Acid.Molecules. 2021 May 14;26(10):2921. doi: 10.3390/molecules26102921. Molecules. 2021. PMID: 34069033 Free PMC article.
References
-
- Brock TG, McNish RW, Peters-Golden M. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem. 1999;274:11660–6. - PubMed
-
- Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735–41. - PubMed
-
- Catella-Lawson F. Vascular biology of thrombosis. Neurology. 2001;57(Suppl 2):S5–S7. - PubMed
-
- Jüni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364:2021–9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
